Bio-Thera Solutions, Ltd. Class A
SSSE:68817717.34
CNY
-0.45
(-2.53%)
ISIN
CNE100003R98
Return %
Stock
S&P 500
1Y
-35.42
14.20
3Y
-42.08
81.12
5Y
-36.13
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Sheng Feng Li
- Full Time Employees
- 1,426
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Guangzhou China
- IPO Date
- Feb 21, 2020
- Website
- bio-thera.com
- Similar Companies
- Business
- Bio-Thera Solutions, Ltd. is a commercial-stage biopharmaceutical company that engages in the research, development, manufacturing, and commercialization of novel therapeutics and biosimilars for the treatment of oncology, autoimmune, cardiovascular, ophthalmic, and other serious medical conditions. Founded in 2003 and headquartered in Guangzhou, China, the company operates integrated research laboratories, advanced antibody discovery platforms, proprietary antibody-drug conjugate (ADC) technologies, and large-scale commercial biomanufacturing facilities compliant with international cGMP standards. Bio-Thera Solutions, Ltd. structures its product offerings and development pipeline across innovative biologics, biosimilar monoclonal antibodies, and targeted conjugate therapies; its commercialized and late-stage clinical portfolio includes Qletli (BAT1406), an adalimumab biosimilar indicated for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and Crohn disease; Pobev / Avzivi (BAT1706), a bevacizumab biosimilar approved for multiple oncology indications including metastatic colorectal cancer, non-small cell lung cancer, and glioblastoma; Tofidence (BAT1806), a tocilizumab biosimilar approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome; BAT2206, an ustekinumab biosimilar candidate for plaque psoriasis, psoriatic arthritis, and inflammatory bowel diseases; BAT2506, a golimumab biosimilar candidate for autoimmune disorders; BAT2306, a secukinumab biosimilar candidate; BAT8006, an investigational folate receptor alpha-targeting antibody-drug conjugate utilizing a proprietary topoisomerase I inhibitor payload for advanced epithelial ovarian and endometrial cancers; BAT8007, a Nectin-4-directed antibody-drug conjugate for advanced solid tumors; BAT8008, a Trop2-directed antibody-drug conjugate; and multiple investigational bispecific antibodies and immuno-oncology agents targeting checkpoint pathways. The company serves healthcare systems, hospitals, and pharmaceutical distribution networks across China, the United States, Europe, and other international markets through direct commercial infrastructure and collaborative distribution agreements. In recent corporate developments, Bio-Thera Solutions, Ltd. has expanded its international market reach through strategic licensing and commercialization alliances with global pharmaceutical partners, including agreements with Biogen Inc. for the commercialization of its tocilizumab biosimilar across the United States and international markets, Sandoz AG for the commercialization of bevacizumab biosimilar BAT1706 in the United States and Europe, and Hikma Pharmaceuticals PLC for the exclusive commercialization of ustekinumab biosimilar BAT2206 in the United States. Additionally, the company secured United States Food and Drug Administration and European Medicines Agency regulatory approvals and commercial launches for its lead biosimilar products, advanced global regulatory submissions for its ustekinumab biosimilar, and expanded clinical evaluation of its proprietary antibody-drug conjugate clinical pipeline into multi-regional oncology trials.